Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease. A preliminary analysis ...

Bristol Myers Squibb (NYSE:BMY) said a Phase 3 study for its drug Zeposia in the treatment of moderate-to-severe active Crohn’s disease failed to meet its primary endpoint of clinical remission ...

The oral S1P1 and S1P5 receptor agonist drug – now given the trade name Zeposia – was billed as one of the top 2020 drug launches to watch by Clarivate last month, before the COVID-19 outbreak ...

With Zeposia (to prevent increasing your blood pressure), you will be asked to avoid meals or snacks that are high in ...

Zeposia, an ulcerative colitis medication, ran Z The Light, a direct-to-consumer campaign aimed at driving awareness, intent to ask doctors for the brand, prescriptions and brand equity. Summary of ...

In October 2020, Bristol Myers Squibb’s Zeposia was approved for the treatment of relapsing-remitting MS (RRMS) with a label that, unlike Gilenya, allowed for prescribing to treatment-naive ...